Detalhe da pesquisa
1.
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Breast Cancer Res
; 26(1): 13, 2024 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38238761
2.
Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
Lab Invest
; 99(9): 1309-1320, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31160689
3.
Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
J Pathol
; 243(3): 307-319, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28741662
4.
Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
BMC Cancer
; 17(1): 535, 2017 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28806950
5.
Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
Mod Pathol
; 28(4): 468-79, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25234288
6.
MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Int J Cancer
; 134(10): 2424-36, 2014 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24615768
7.
Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer.
Cancer Res Treat
; 55(1): 145-154, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468270
8.
Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma.
Cancer Res Treat
; 55(2): 452-467, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265509
9.
TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis.
Cancer Res Treat
; 53(1): 9-24, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32972043
10.
IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer.
Mol Ther Oncolytics
; 16: 188-196, 2020 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32099898
11.
Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer.
Cancers (Basel)
; 12(6)2020 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32549194
12.
Molecular changes in solitary fibrous tumor progression.
J Mol Med (Berl)
; 97(10): 1413-1425, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31321477
13.
Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
Cancer Biol Ther
; 19(4): 335-345, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29333926
14.
Integrin ß3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC.
Clin Cancer Res
; 24(17): 4162-4174, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29776956
15.
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
J Thorac Oncol
; 12(8): 1233-1246, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28502721
16.
Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma.
Oncotarget
; 7(17): 24141-53, 2016 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27007161
17.
LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Oncotarget
; 7(50): 82876-82888, 2016 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27756880
18.
HER2 as a novel therapeutic target for cervical cancer.
Oncotarget
; 6(34): 36219-30, 2015 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26435481
19.
Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR.
Oncotarget
; 6(7): 5465-74, 2015 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25760072